Disease Landscape and Forecast Insights

The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving non-TNF-α inhibitor agents to…

Abstract Introduction: The Emerging Biosimilars Overview offers extensive coverage of the global biosimilar development landscape. We track over 350 currently available and novel biosimilar…

In late age-related macular degeneration (AMD), vision deficits are noticeable, are often debilitating, and can be a precursor to blindness. The availability of vascular endothelial growth factor (…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor-alpha (TNF-alpha) inhibitors and interleukin-12 and…

Multiple label expansions of premium-priced agents and the launch of seven novel therapies will fuel the significant growth of the NHL market over the ten-year forecast period. The biosimilar…

A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United…

Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available therapeutic options are premium-priced targeted agents and chemotherapy…

The uptake of biosimilar erythropoiesis-stimulating agents (ESAs) varies from country to country, as well as by drug and manufacturer. European nephrologists have been able to prescribe ESAs to…

Five TNF-α inhibitors and four biologics with alternative mechanisms of action are currently approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy, Spain,…

Abstract Introduction: With a growing number of biosimilars in development and the launch of the first FDA-approved products in 2015, biosimilars are set to gain an increasing share of the…

The U.S. rheumatoid arthritis (RA) market is crowded, with the availability of nine different biologics and Xeljanz, representing six distinct drug classes. With the impending entry of biosimilars…

Abstract: The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…